Pharmaceuticals
/DISREGARD RELEASE: Ractigen Therapeutics/
We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued7:30AM 12-Dec-2025 over PR Newswire, as the release contained erroneous information...
2025-12-12 23:10
915
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio")announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and p...
2025-12-12 22:00
1114
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH...
2025-12-12 21:35
1173
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. * The partnership combines Insilico's generative AI ...
2025-12-12 20:00
759
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study wi...
2025-12-12 10:31
1025
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
* After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI r...
2025-12-12 08:00
1127
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol * This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial * Next steps include obtaining single IRB approval, site initiations and cl...
2025-12-12 04:49
1068
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as th...
2025-12-12 00:21
1308
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-bindin...
2025-12-11 23:57
1143
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechn...
2025-12-11 21:00
994
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...
2025-12-11 14:12
1681
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
* Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases * OTR Therapeut...
2025-12-11 14:00
1144
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment...
2025-12-11 09:53
914
Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southernChina, carrying profound historical heritage and unique clinical value.The Seventh World Hakka Entrepreneurs Conven...
2025-12-11 08:00
1011
Samsung Biologics recognized as a global leader in water security
* Company receives the highest Water Security rating in two years into participation * Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing or...
2025-12-11 07:30
905
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...
2025-12-11 03:30
1156
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk
Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals")
and Formation Bio
2025-12-10 22:05
1671
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at theUniversity of Rocheste...
2025-12-10 21:00
1210
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 ...
2025-12-10 17:15
857
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day inShanghai. The event focused on the latest advancements in the field of antibody-drug c...
2025-12-10 14:20
963
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4944
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
4030
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3921
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3416
Cyient Semiconductors Qualifies for Key Bid in Semi-Conductor Laboratory-Mohali Revamp
2025-12-06 02:00
2679